Migraine drug eptinezumab tested for Long-Term safety in japanese patients
NCT ID NCT05064371
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at the long-term safety of eptinezumab, a drug given by IV infusion to prevent migraines. It included 160 Japanese patients who had already completed a previous study. The main goal was to see if the drug is safe and tolerable over 60 weeks of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
eptinezumab
What this could lead to
If successful, this could confirm that eptinezumab is safe for long-term use to prevent migraines, offering a reliable treatment option.
What could go wrong
This is an extension study focused on safety, not on proving how well it works. It is also limited to Japanese participants, so results may not apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atsuchi Neurosurgery Hospital
Kagoshima, Kagoshima-ken, 892-0842, Japan
-
DOI Clinic Internal Medicine
Hiroshima-Shi Naka-Ku, Hiroshima, 730-0031, Japan
-
Dokkyo Medical University Hospital
Mibu-machi, 321-0293, Japan
-
Ikeda Neurosurgical Clinic
Kasuga-Shi, Hukuoka, 816-0824, Japan
-
Iwate Medical University Uchimaru Medical Center
Morioka, Iwate, 020-0023, Japan
-
Japanese Red Cross Shizuoka Hospital
Shizuoka, 420-0853, Japan
-
Jinnouchi Neurosurgery Clinic
Kasuga-Shi, Hukuoka, 816-0802, Japan
-
Mito Kyodo General Hospital
Mito, Ibaraki, 310-0015, Japan
-
Moriyama Neurological Center Hospital
Edogawa-Ku, Tokyo, 134-0085, Japan
-
Nagamitsu Clinic
Hofu-Shi, Yamaguchi, 747-0802, Japan
-
Saitama Neuropsychiatric Institute
Saitama-Shi, Saitama, 338-8577, Japan
-
Sendai Headache and Cranial Nerves Clinic
Sendai-Shi Taihaku-Ku, Miyagi, 982-0014, Japan
-
Shin Matsudakai Atago Hospital
Kochi, Kôti, 780-0051, Japan
-
Tatsuoka Neurology Clinic
Kyoto Shimojo-ku, 680-8811, Japan
-
Tokyo headache clinic
Shibuya-Ku, Tokyo, 151-0051, Japan
-
Tominaga Hospital
Osaka, Ã"saka, 556-0017, Japan
-
Toyota Memorial Hospital
Toyota-shi, 471-8513, Japan